ECG247 Smart Heart Sensor

09/07/2025

Advancing Arrhythmia Diagnostics: Insights from the Medical University of Lodz. At the International Congress on Electrocardiology 2025 (ISHNE & ISE) in Thessaloniki, Greece, experiences with the use of ECG247 at the Medical University of Lodz, Poland, were presented by Professor Andrzej Bissinger MD PhD FESC. He concluded that ECG247 can contribute to improved and more efficient arrhythmia diagnostics in clinical practice.

19/05/2025

🌟 Are you interested in learning more about the NORSCREEN study, the world's largest screening study for atrial fibrillation? Join us at the Startup Zone at to discover more! We look forward to seeing you there! 🌟

14/05/2025

ECG247 is excited to announce our presence at the conference in Helsinki, Finland, this year! We will be showcasing our innovative heart sensor, , in the start-up zone alongside other promising start-ups. We invite you to visit our booth to learn more about ECG247 and discover how our technology can effectively screen for atrial fibrillation. We look forward to connecting with you!

30/03/2025

Due to growing demand for ECG247 from hospitals and clinics in Norway and internationally, we are expanding our team. Our advanced solution for long-term heart rhythm monitoring has undergone significant technological advancements, making it a robust, scalable, and highly attractive option in variou...

11/01/2025

ECG247 in the Tromsø Study!

The Tromsø Study, initiated in 1974 in response to the high cardiovascular disease mortality rates in Northern Norway, has since evolved into a series of seven studies conducted at 7-8 year intervals. The eighth Tromsø Study is scheduled for 2025-2026 and will involve 4,000 participants with elevated NT-proBNP levels. Participants will be randomized to atrial fibrillation screening using ECG247. Outcomes in the intervention group will be compared to those in the control group regarding stroke incidence and mortality over a six-year follow-up period.

For ECG247, it is a vote of confidence that another leading research community chooses to use Norwegian medical technology. ECG247 is also in use in the Norwegian national atrial fibrillation screening study NORSCREEN and in the Nord-Trøndelag Health Study (HUNT). The ECG247 is highly cost-effective and requires minimal personnel resources.

08/01/2025

New trial published: ECG247 is highly suitable for evaluating heart rhythm disorders in athletes

Researchers from Bærum Hospital and St. Olavs Hospital, in collaboration with colleagues from Belgium and Australia, conducted a comparative study between ECG247 and implantable loop recorders. The study concluded that ECG247 is highly suitable for evaluating heart rhythm disorders in athletes, successfully detecting all arrhythmias identified by the loop recorders in the study participants.

This study represents another important clinical validation of ECG247. As a more cost-effective and user-friendly alternative to implantable loop recorders, ECG247 has the potential to facilitate faster patient evaluations and help reduce hospital waiting lists.

Read the paper in BMJ Open: https://bmjopen.bmj.com/content/15/1/e093250

22/11/2024

In the fourth Trøndelag Health Study (HUNT4, 2017-2019), NTNU, Trondheim, over 2,400 participants were examined with cardiac ultrasound and a treadmill exercise test. In a new project, these participants will now be examined for heart rhythm disorders with ECG247. The goal of the project is, among ...

13/11/2024

International Medical Center, Cairo, Egypt

ECG247 has conducted the first training for a customer in Cairo, Egypt. The International Medical Center (IMC) in Cairo will be the first to introduce ECG247 to its patients. IMC is one of the largest tertiary hospitals in the Middle East, with 800 beds. It is part of the Ministry of Defense and the Egyptian Armed Forces. The hospital sees excellent technological advantages that can ensure effective and continuous long-term cardiac monitoring.

Together with the local distribution partner EGMED, ECG247 will offer services for public and private hospitals in Egypt. EGMED has over 40 years of experience and is a market leader in supplying hospitals and clinics in Egypt, the Middle East, and Africa.

EGMED

ECG247 has conducted the first training for a customer in Cairo, Egypt. The International Medical Center (IMC) in Cairo will be the first to introduce ECG247 to its patients. IMC is one of the largest tertiary hospitals in the Middle East, with 800 beds. It is part of the Ministry of Defense and

08/11/2024

Meet us at MEDICA

05/10/2024

The NORSCREEN trial is one of the largest AF screening RCTs ever. The study will include 35 000 participants and use ECG247 for heart rhythm monitoring. Read more about the study in this article in EP Europace

AbstractAims. Atrial fibrillation (AF) is a common arrhythmia, and many cases of AF may be undiagnosed. Whether screening for AF and subsequent treatment i

24/09/2024

The Chua & Arif Specialist Clinic in Bandar Seri Begawan in Brunei uses the ECG247 on its patients. “It is good to have an offer for everyone who visits our clinic with palpitations. With the ECG247, we get good recordings over 72 hours that have been difficult to achieve with traditional Holter d...

22/09/2024

ECG247 in new countries. We were today certified by the South African Health Products Regulatory Authority (SAPHRA) for use in South Africa. Thanks to our distributor in South Africa, Teledoctor SA, for a comprehensive job. ECG247 will contribute to easier and better assessment of heart rhythm disorders in South Africa as well.